Eduovisual
Pregnancy, Childbirth & Puerperium
Ectopic pregnancy: diagnosis and management
— Even amenorrhea without classic pain warrants pregnancy testing if presenting with shoulder-tip pain, near-syncope, or unexplained anemia.
— Heterotopic pregnancy (intrauterine + ectopic simultaneously) is rare in spontaneous conceptions (~1:30,000) but rises to ~1:100 with ART/IVF — do not be reassured by an IUP on ultrasound in an ART patient.
— Prior ectopic (recurrence ~10%), prior tubal surgery (including ligation), PID/chlamydia/gonorrhea history, endometriosis.
— IUD in place at conception — the absolute risk is low because IUDs prevent pregnancy overall, but if pregnancy occurs with an IUD, it is disproportionately ectopic.
— Assisted reproductive technology, tubal pathology on HSG, smoking, age >35, DES exposure (historical).
Board pearl: A reproductive-age woman with syncope, shoulder pain, or unexplained hypotension gets a urine β-hCG before anything else — the question stem may bury the LMP detail or call her "regular" while describing 6 weeks of amenorrhea.
Step 3 management: Establish IV access, type & screen, quantitative β-hCG, and transvaginal US in parallel — not sequentially — when suspicion is high.
— Often 6–8 weeks from LMP, but ranges 4–12 weeks; interstitial/cornual ectopics rupture later (8–12 weeks) because the myometrium accommodates growth — and rupture catastrophically.
— Pain may be dull and crampy early, becoming sharp, lateralized, or diffuse; shoulder-tip pain = diaphragmatic irritation from hemoperitoneum.
— Bleeding is typically light/spotting and dark ("prune juice"); heavy bleeding with clots favors threatened/incomplete abortion instead.
— Syncope, lightheadedness, or urge to defecate (pelvic blood pooling in cul-de-sac) = rupture until proven otherwise.
— LMP certainty, cycle regularity, contraception (especially IUD, tubal ligation, progestin-only methods).
— Prior ectopic, prior pelvic/tubal surgery, STI history, infertility treatment (IVF, ovulation induction).
— Pregnancy intent and prior obstetric outcomes — also frames counseling for methotrexate vs. surgery.
— Medications/allergies relevant to methotrexate eligibility (folate, NSAIDs, PPIs).
— Painless bleeding mimicking miscarriage.
— GI complaints (nausea, diarrhea) from peritoneal blood.
— Persistent ectopic after salpingostomy or methotrexate — recurrent rising β-hCG weeks later.
Key distinction: Threatened abortion vs. ectopic — both present with bleeding and pain in early pregnancy, but lateralized pain, adnexal tenderness, and a β-hCG that fails to rise appropriately push you toward ectopic. Definitive separation requires US ± serial β-hCG.
Board pearl: A patient who underwent tubal ligation years ago and now presents with pelvic pain and a positive pregnancy test has an ectopic until proven otherwise — sterilization failures are disproportionately ectopic.
Step 3 management: Document last contraception, last menses, and ART status in the H&P — these directly drive your pretest probability and the differential weighting on the answer choices.
— Tachycardia is the earliest sign of hemorrhage; young patients compensate BP until late. A pulse of 110 in a thin 25-year-old with pelvic pain is a red flag.
— Hypotension, narrow pulse pressure, cool extremities, delayed cap refill → assume ruptured ectopic, activate massive transfusion thinking.
— Orthostatic vitals are useful in borderline cases but should not delay resuscitation.
— Localized lower quadrant tenderness early; rebound, guarding, and rigidity suggest hemoperitoneum.
— Cullen sign (periumbilical ecchymosis) is rare but classic for retroperitoneal/intraperitoneal blood.
— Distension with shifting dullness in late presentations.
— Speculum: small amount of dark blood at the os, closed cervix (open os shifts toward inevitable/incomplete abortion).
— Bimanual: cervical motion tenderness, adnexal tenderness, or a palpable adnexal mass; uterus often smaller than expected for dates.
— Fullness in the posterior cul-de-sac suggests blood.
— Unstable (SBP <90, HR >120, signs of shock, peritonitis): straight to OR, bypass advanced imaging.
— Stable with concerning exam: transvaginal US, quantitative β-hCG, type & screen, CBC, Rh status, two large-bore IVs.
— Stable, mild symptoms, early gestation: outpatient workup is acceptable with reliable follow-up.
CCS pearl: On CCS, in a hypotensive patient with positive β-hCG and free fluid, your next orders are simultaneous, not sequential: 2 large-bore IVs, IV crystalloid bolus, CBC, type & crossmatch (not just type & screen), Rh, coags, OB/GYN consult, OR notification — then transvaginal US only if it does not delay the OR.
Board pearl: A "soft" abdomen with disproportionate pain on cervical motion in a pregnant patient is high-yield for ectopic — this is the chandelier sign in disguise.
— Discriminatory zone: β-hCG ~3,500 mIU/mL (ACOG-updated, more conservative than older 1,500–2,000 cutoff) — above this, a normal IUP should be visible on TVUS. No IUP above the discriminatory zone = high suspicion for ectopic or nonviable pregnancy.
— Serial β-hCG: A viable IUP typically rises ≥35% in 48 hours (older "doubling" rule was too strict). A plateau, sluggish rise, or inappropriate drop suggests nonviable pregnancy (ectopic or failing IUP) — but does not localize.
— β-hCG that falls ≥21% in 48 hours suggests completed/failing intrauterine pregnancy, though ectopics can also resolve spontaneously.
— Findings that confirm IUP: gestational sac with yolk sac or fetal pole inside uterus. A pseudogestational sac (decidual reaction with fluid) can mimic IUP in ~10–20% of ectopics — look for double decidual sign.
— Ectopic findings: extraovarian adnexal mass, "ring of fire" on Doppler, tubal ring sign, free fluid (especially echogenic) in cul-de-sac, live extrauterine embryo (pathognomonic).
— CBC (baseline Hgb, trend if bleeding), type and Rh (Rh-negative → RhoGAM 50–300 mcg), basic metabolic panel.
— Progesterone is not standard but <5 ng/mL suggests nonviable pregnancy; >25 ng/mL suggests viable IUP — used adjunctively.
— Coags and crossmatch if unstable.
Key distinction: β-hCG trend matters more than single value for stable patients — a single low β-hCG with no IUP on US could be a very early IUP or an ectopic; repeat in 48 hours.
Board pearl: No IUP + β-hCG above discriminatory zone = ectopic or nonviable pregnancy, not "too early." Do not reassure the patient and send home.
Step 3 management: Always check Rh status early — Rh-negative patients with bleeding in any first-trimester pregnancy loss/ectopic get anti-D immunoglobulin.
— Defined as positive β-hCG with no IUP and no clear extrauterine pregnancy on TVUS.
— Strategy: serial β-hCG every 48 hours + repeat TVUS, plus close clinical follow-up.
— Outcomes split roughly: ~50% failing IUP, ~30% viable IUP (too early), ~20% ectopic.
— Repeat when β-hCG crosses the discriminatory zone or in 48–72 hours if rising abnormally.
— Look for new adnexal findings, interval growth of an IUP, or completed miscarriage.
— When β-hCG plateaus or rises abnormally and US is nondiagnostic, D&C distinguishes failed IUP (chorionic villi present) from ectopic (no villi, β-hCG that doesn't fall ≥50% in 12–24 hours post-procedure).
— Especially useful when patient wants to avoid unnecessary methotrexate that could harm a desired viable pregnancy.
— Gold standard when imaging and labs remain equivocal and clinical suspicion is high — both diagnostic and therapeutic.
— Indicated for hemodynamically unstable patients or persistently inconclusive cases.
Board pearl: A β-hCG that drops <15% after uterine aspiration essentially confirms persistent trophoblastic tissue outside the uterus — i.e., ectopic.
Key distinction: Heterotopic pregnancy in an IVF patient — finding an IUP does not exclude a coexisting ectopic; carefully scan adnexa even with a confirmed IUP.
Step 3 management: Counsel PUL patients on strict return precautions — worsening pain, syncope, heavy bleeding — and ensure 48-hour β-hCG follow-up is scheduled before they leave.
— Immediate surgery (laparoscopic or laparotomy) with resuscitation. Do not pursue medical therapy.
— Eligibility criteria (must meet all):
— Hemodynamic stability, no signs of rupture, reliable follow-up.
— β-hCG <5,000 mIU/mL (best success; up to 15,000 acceptable in some protocols but lower success).
— No fetal cardiac activity on US.
— Ectopic mass <3.5–4 cm.
— Normal renal/hepatic function, normal CBC, no immunodeficiency.
— No contraindications: breastfeeding, peptic ulcer, active pulmonary/hepatic disease, blood dyscrasia, coexistent viable desired IUP (heterotopic).
— Laparoscopic salpingostomy or salpingectomy.
— Salpingectomy preferred if contralateral tube healthy or tube ruptured/severely damaged; salpingostomy preserves tube but has higher persistent trophoblast risk.
— Highly selective: β-hCG <200 mIU/mL and falling, asymptomatic, no/minimal mass, reliable follow-up. ~70–90% resolve spontaneously.
Step 3 management: Shared decision-making is testable — present methotrexate vs. surgery with success rates (~85–90% MTX in well-selected patients), future fertility implications (similar IUP rates after MTX vs. salpingostomy), and follow-up burden (weekly β-hCGs until undetectable for MTX).
Board pearl: Fetal cardiac activity in an ectopic = surgery, not methotrexate — high failure rate with medical therapy.
Key distinction: Salpingostomy preserves the tube but requires post-op β-hCG surveillance for persistent ectopic (~5–15%); salpingectomy is definitive but removes the tube.
— Single-dose: 50 mg/m² IM on day 1. Check β-hCG on days 4 and 7. Expect ≥15% decline between days 4 and 7; if not, give a second dose. Repeat weekly β-hCG until undetectable (often 4–6 weeks).
— Most commonly used; lowest side-effect burden; ~85% success.
— Two-dose: 50 mg/m² IM on days 0 and 4, with β-hCG monitoring. Slightly higher success in moderate β-hCG levels.
— Multi-dose: 1 mg/kg IM alternating with leucovorin 0.1 mg/kg on days 1,3,5,7. Reserved for higher β-hCG or interstitial ectopics; more toxicity.
— CBC, LFTs, creatinine, type & Rh, β-hCG, blood type.
— Confirm no contraindications (renal/hepatic disease, peptic ulcer, immunosuppression, active pulmonary disease, breastfeeding, alcohol use disorder).
— Avoid folic acid supplements, NSAIDs, sulfa antibiotics, and PPIs during treatment — all reduce efficacy or amplify toxicity.
— Counsel: no alcohol, no sun exposure (photosensitivity), no sexual intercourse until resolution, reliable contraception for ≥3 months post-treatment (teratogen).
— "Separation pain" around days 3–7 from tubal distension/abortion — common and benign if vitals stable; differentiate from rupture (worsening pain + hypotension/anemia).
— Side effects: nausea, stomatitis, transaminase elevation, mild bone marrow suppression.
Step 3 management: A patient on day 5 post-MTX calls with abdominal pain — check vitals, CBC, and recheck US/β-hCG. Stable + Hgb stable = likely separation pain. Hypotension or rebound = rupture, OR.
Board pearl: β-hCG often rises slightly between day 1 and day 4 after MTX — this is normal and not a treatment failure. The day 4–7 trend is what counts.
— Indicated for: ruptured tube, severe tubal damage, uncontrolled bleeding, recurrent ipsilateral ectopic, completed childbearing, or healthy contralateral tube.
— Definitive — no risk of persistent trophoblast.
— Future fertility: comparable IUP rates to salpingostomy when contralateral tube is healthy.
— Indicated when contralateral tube is absent/damaged and patient desires fertility preservation.
— Requires post-op weekly β-hCG monitoring until undetectable — 5–15% persistent trophoblast rate; treat with single-dose MTX.
— Interstitial/cornual ectopic: cornual resection or wedge resection; high rupture risk later in gestation; consider MTX for early stable cases.
— Cesarean scar ectopic: combined approaches (MTX ± uterine artery embolization, hysteroscopic/laparoscopic resection); high hemorrhage risk.
— Cervical ectopic: MTX preferred; D&C dangerous due to hemorrhage; uterine artery embolization adjunct.
— Ovarian and abdominal ectopics: surgical resection; abdominal ectopics may require leaving the placenta in situ with MTX.
— Type & cross, large-bore IV access, Rh status, antibiotic prophylaxis per protocol.
— Anti-D immunoglobulin for Rh-negative patients post-op.
CCS pearl: For an unstable patient, your CCS orders cluster looks like: 2 large-bore IVs, IVF bolus, type & cross 2–4 units PRBCs, CBC, coags, OB/GYN consult, NPO, consent for laparoscopy possible laparotomy, anesthesia consult, OR.
Board pearl: Cervical and cesarean scar ectopics → think methotrexate first; sharp instrumentation can precipitate catastrophic hemorrhage requiring hysterectomy.
Key distinction: Salpingostomy + persistent trophoblast → adjunctive MTX, not a failure of judgment — it's an expected complication requiring surveillance.
— Methotrexate is renally cleared — even mild CKD prolongs half-life and amplifies marrow, GI, and hepatic toxicity.
— Avoid MTX if CrCl <60 mL/min or serum Cr above normal; if absolutely necessary, dose reduce and obtain hematology/oncology input. Surgery preferred.
— Dehydration from hyperemesis or GI losses can transiently reduce clearance — correct before dosing.
— MTX causes transient transaminase elevation; baseline AST/ALT >2× ULN or known liver disease (hepatitis, fatty liver with fibrosis, chronic alcohol use) is a contraindication.
— Recheck LFTs at day 7 and as needed.
— Avoid MTX with anemia (Hgb <10), leukopenia (WBC <3,000), or thrombocytopenia (plt <100k).
— Active bleeding ectopic with falling Hgb → surgical, not medical, management.
— NSAIDs, salicylates → displace MTX from albumin, increase toxicity.
— Trimethoprim-sulfamethoxazole, dapsone → additive antifolate, marrow suppression.
— PPIs, probenecid → reduce renal clearance.
— Penicillins → reduce tubular secretion of MTX.
— Folic acid–containing prenatal vitamins → competitive antagonism, hold during MTX therapy.
Step 3 management: Before signing the MTX order, explicitly review the med list and discontinue NSAIDs, PPIs, and folate supplements; document patient education and counseling on alcohol and sun avoidance.
Board pearl: MTX + TMP-SMX = pancytopenia. A patient on chronic Bactrim prophylaxis (HIV, transplant) is generally not a methotrexate candidate.
Key distinction: Mild LFT elevation post-MTX is expected and self-resolving; persistent elevation or symptoms warrants hepatology input and halts further dosing.
— High-risk for ectopic due to higher STI rates and underdiagnosed PID.
— Confidentiality: In most US states, minors can consent to STI testing, contraception, and pregnancy-related care without parental consent — but emancipation laws vary. Document carefully.
— Always offer comprehensive STI testing (GC/CT, HIV, syphilis) and contraceptive counseling at discharge.
— Heterotopic pregnancy rate up to 1:100 with IVF — confirming an IUP does not rule out a coexisting ectopic. Always scan adnexa carefully.
— Higher rates of unusual implantation sites (cornual, cervical, cesarean scar).
— Methotrexate is teratogenic — avoid if heterotopic with desired viable IUP; surgical removal of ectopic with IUP preservation is preferred (laparoscopic salpingectomy is generally compatible with continuing IUP).
— After one ectopic: subsequent IUP rate ~60%, recurrent ectopic ~10%, infertility ~10–15%.
— No significant fertility difference between salpingectomy and salpingostomy when contralateral tube is healthy.
— In patients with prior tubal damage or bilateral tubal disease: IVF often outperforms surgical preservation.
— Methotrexate does not impair future fertility but requires 3-month contraception interval before next conception attempt (teratogen washout, folate stores).
Board pearl: 3 months of reliable contraception after methotrexate before attempting conception — frequently asked.
Step 3 management: Schedule a postpartum/post-ectopic visit at 1–2 weeks for emotional support, contraception, and STI follow-up — the grief response is real and frequently overlooked.
— Tubal rupture and hemoperitoneum → hypovolemic shock, DIC, death. Most preventable with early diagnosis.
— Persistent ectopic pregnancy after salpingostomy or incomplete MTX response (~5–15% post-salpingostomy, ~5–10% post-MTX) — manifests as plateau or rising β-hCG; treated with additional MTX or completion salpingectomy.
— Methotrexate toxicity: stomatitis, transaminitis, marrow suppression, alopecia, pneumonitis (rare), nephrotoxicity.
— Surgical complications: bleeding, infection, adhesions, injury to bladder/bowel/ureter, anesthesia risk, VTE.
— Recurrent ectopic (~10% lifetime risk after one; ~25% after two).
— Infertility in 10–15%, especially with prior tubal damage.
— Rh sensitization if anti-D omitted.
— Pelvic adhesions from hemoperitoneum or surgery.
— Pregnancy loss carries significant grief; depression and anxiety are common at 1–3 months post-ectopic.
— Screen with PHQ-9 at follow-up; offer counseling or referral; acknowledge the loss explicitly.
— Interstitial rupture → catastrophic hemorrhage from uterine artery branches, often requiring hysterectomy.
— Cervical ectopic → uncontrolled hemorrhage if instrumented blindly.
— Abdominal ectopic → placental implantation on bowel/mesentery; leaving placenta in situ risks abscess, sepsis, and prolonged β-hCG resolution.
Key distinction: Separation pain (MTX day 3–7) vs. rupture: separation pain is self-limited with stable vitals and Hgb; rupture has worsening pain plus hemodynamic change.
Board pearl: Failure to give anti-D immunoglobulin to an Rh-negative patient is a classic patient-safety vignette and a malpractice trigger.
Step 3 management: Every post-ectopic follow-up note should document: β-hCG trend, contraception plan, anti-D administration, emotional well-being screening, and future fertility counseling.
— Any confirmed or strongly suspected ectopic pregnancy.
— PUL with concerning trajectory (rising pain, falling Hgb, β-hCG plateau).
— All MTX candidates — OB confirms eligibility and arranges follow-up.
— Hemodynamic instability (SBP <90, HR >120, signs of shock).
— Peritoneal signs, large hemoperitoneum on US, syncope.
— Falling Hgb with confirmed ectopic.
— Massive transfusion (>4 units PRBCs in 24 h), persistent hemodynamic instability despite resuscitation.
— DIC, post-operative respiratory or cardiovascular compromise.
— Severe MTX toxicity (pancytopenia with sepsis, severe pneumonitis, AKI requiring dialysis).
— Severe pain limiting oral intake, uncertain follow-up, social/transportation barriers.
— Borderline vitals or Hgb that don't quite meet rupture criteria but warrant trending.
— Patients far from a hospital who would not safely return in case of rupture.
— Community ED without OB/GYN coverage → transfer to facility with surgical and blood bank capacity after initial resuscitation and stabilization.
— Do not delay transfer for confirmatory imaging when a clinically unstable pregnant patient is in front of you.
— Interventional radiology for uterine artery embolization in cervical or cesarean scar ectopics.
— Hematology for severe MTX toxicity.
— Behavioral health for grief or postpartum-spectrum symptoms.
CCS pearl: When advancing the CCS clock, set vital sign rechecks every 15–30 minutes for unstable patients, every 1–2 hours for borderline, and serial β-hCG/CBC at appropriate intervals for stable MTX patients. Don't forget to schedule the follow-up clinic visit before ending the case.
Board pearl: A patient with confirmed ectopic who lives alone, is far from a hospital, or has unreliable transport is not a methotrexate candidate — surgery or admission is safer.
Step 3 management: Always confirm and document who the patient will call and how she'll get to the ER if symptoms worsen — this is a tested patient-safety detail.
— Cramping midline pain with bleeding; cervical os may be open (inevitable/incomplete) or closed (threatened/complete).
— TVUS shows intrauterine findings (gestational sac, products of conception, or empty uterus with prior IUP confirmed).
— β-hCG typically falling appropriately after complete miscarriage.
— Embryonic demise with retained products; IUP visible on US but no cardiac activity at appropriate gestational age (e.g., crown-rump length ≥7 mm without cardiac activity).
— β-hCG plateaus or falls slowly; no extrauterine findings.
— Markedly elevated β-hCG (often >100,000), hyperemesis, early preeclampsia, "snowstorm" or cluster-of-grapes pattern on US.
— Complete mole: no fetus, diffuse hydropic villi. Partial mole: fetal parts present.
— Treatment: D&C, then β-hCG surveillance for persistent GTD/choriocarcinoma.
— Coexisting IUP and ectopic — disproportionately in ART patients.
— Confirming an IUP does NOT rule out ectopic; persistent pain or adnexal mass after seeing IUP demands further evaluation.
— Pain with positive β-hCG and IUP on US; adnexal mass may mimic ectopic; lacks "ring of fire" within tube.
— Usually self-limited unless significant hemoperitoneum.
— Bleeding with IUP and US showing hypoechoic crescent adjacent to gestational sac; managed expectantly.
Key distinction: Open cervical os + bleeding + cramping = inevitable/incomplete abortion; closed os + lateralized pain + adnexal mass + abnormal β-hCG trend = ectopic.
Board pearl: β-hCG of 150,000 at 9 weeks with hyperemesis and early-onset hypertension = molar pregnancy, not ectopic — pivot the workup.
Step 3 management: Distinguishing failed IUP from ectopic when US is indeterminate may require D&C as a diagnostic step before committing to MTX.
— RLQ pain, anorexia, fever, leukocytosis; can occur in pregnancy and is the most common non-OB surgical emergency.
— Pregnant patients: appendix displaced superiorly/laterally with gestation. MRI without contrast preferred imaging in pregnancy if US nondiagnostic.
— Fever, cervical motion tenderness, mucopurulent discharge, bilateral adnexal tenderness; negative pregnancy test (usually).
— TOA on US shows complex adnexal mass with septations and fluid.
— Sudden severe unilateral pelvic pain, nausea/vomiting, palpable adnexal mass; Doppler US shows decreased ovarian flow.
— Surgical emergency — detorsion within hours preserves ovary.
— Sudden pain after exertion/intercourse, free fluid on US; usually self-limited.
— Flank-to-groin colicky pain, hematuria; CT or US in pregnancy.
— Dysuria, frequency, fever, CVA tenderness; pyuria and bacteriuria on UA.
— Diverticulitis, mesenteric adenitis, IBD flare, gastroenteritis.
— Chronic cyclic pelvic pain, dysmenorrhea, dyspareunia; not acute but a differential in subacute presentations.
Key distinction: Ovarian torsion mimics ectopic when both present with sudden unilateral pelvic pain; pregnancy test and Doppler flow assessment differentiate — torsion typically has minimal/absent flow with enlarged ovary, while ectopic has an adnexal ring with "ring of fire."
Board pearl: Always check a pregnancy test before ordering CT for abdominal pain in a reproductive-age woman — both to rule in ectopic and to protect a potential IUP from radiation.
Step 3 management: When the differential is broad, β-hCG + TVUS + urinalysis is the efficient first cluster — it triages most reproductive-age pelvic pain.
— Discuss all options before discharge; document chosen method.
— After MTX: reliable contraception for at least 3 months (teratogen washout, folate normalization).
— IUDs are not contraindicated after ectopic; copper or LNG IUDs are acceptable once intrauterine pregnancy is fully resolved. Sterilization, implants, OCPs, DMPA, and barrier methods are all on the table.
— Future ectopic risk is not contraception-driven — it relates to the underlying tubal pathology; effective contraception actually reduces total ectopic risk by reducing pregnancies.
— Test for chlamydia and gonorrhea, HIV, syphilis if not recently done — undiagnosed PID is a leading reversible risk factor.
— Treat partner; counsel on barrier protection.
— Smoking is an independent ectopic risk factor (impairs tubal motility). Offer counseling, nicotine replacement, varenicline/bupropion as appropriate.
— Resume prenatal/multivitamin with folic acid after MTX clearance (typically after 3 months) to prepare for future pregnancy.
— Recommend early TVUS at 6–7 weeks in next pregnancy to confirm location.
— Discuss recurrent ectopic risk (~10%) and IVF as an option if bilateral tubal disease.
— Pregnancy loss support, counseling referrals, screen for depression/anxiety.
Board pearl: A patient on MTX who conceives within 3 months is at risk for fetal aminopterin syndrome (cranial dysostosis, limb abnormalities) — strict contraception is essential.
Step 3 management: Write discharge orders explicitly: contraception method + start date, STI panel results/treatment, anti-D given, return precautions, follow-up appointment date, mental health resources.
Key distinction: Contraception is about preventing a future pregnancy until ready — not about preventing future ectopic. Risk reduction comes from treating modifiable factors (smoking, STIs).
— Post-MTX: β-hCG on days 4 and 7, then weekly until undetectable (<5 mIU/mL). Typical resolution in 4–6 weeks; can take up to 8.
— Post-salpingostomy: weekly β-hCG until undetectable to detect persistent trophoblast.
— Post-salpingectomy: β-hCG often checked to confirm resolution but not always necessary if surgery clearly complete; many institutions still trend.
— Expectant management: β-hCG every 48–72 hours until clearly falling, then weekly until undetectable.
— Phone or clinic check within 1 week for MTX patients — assess symptoms, side effects, β-hCG trend.
— Clinic visit at 2–4 weeks for emotional support, contraception, and STI follow-up.
— Re-image only if β-hCG plateaus, rises, or symptoms recur.
— Reinforce contraception, smoking cessation, STI prevention.
— Address grief — name it, acknowledge it, screen with PHQ-9; refer if scores are elevated or grief is prolonged.
— Discuss future pregnancy plan and early-US protocol.
— Review return precautions: any pain, bleeding, dizziness, shoulder pain warrants urgent re-evaluation, especially during the active MTX/expectant period.
— Annual well-woman care, cervical cancer screening per USPSTF, STI screening if risk factors persist.
— Document the ectopic in the problem list to flag future pregnancies for early evaluation.
Step 3 management: A patient post-MTX whose β-hCG plateaus or rises after day 7 needs a second MTX dose or surgical intervention — don't passively continue weekly draws.
Board pearl: β-hCG should fall ≥15% between days 4 and 7 post-single-dose MTX; otherwise, retreat or operate.
CCS pearl: Always close the loop on CCS by scheduling follow-up labs and an OB clinic visit — the case is not complete without it.
— Methotrexate vs. surgery: present both options with risks, success rates, fertility implications, monitoring burden, and contraindications. Document shared decision-making.
— Salpingostomy vs. salpingectomy: discuss future fertility, persistent ectopic risk, and that bilateral tubal preservation may not change IVF need.
— Patients with religious objections to abortion sometimes equate ectopic treatment with abortion — clarify that treatment of ectopic pregnancy is life-saving and is not classified as elective abortion by major medical organizations; most religious traditions permit it under principles of double effect.
— State laws restricting abortion explicitly exempt ectopic pregnancy management in most jurisdictions, but ambiguous statutes have created clinician hesitation in some states.
— Document medical necessity clearly: imaging findings, β-hCG trend, clinical risk of rupture, life-threatening nature.
— Do not delay care due to legal uncertainty — delay risks rupture and death. Hospital legal/ethics consultation available if institutional policy unclear.
— Minors generally can consent to pregnancy-related care without parental involvement under most state laws; document carefully and offer family involvement if patient consents.
— If pregnancy in a minor raises concern for sexual abuse, statutory rape, or trafficking, mandatory reporting laws apply per state. Use a trauma-informed approach.
— Missed diagnosis in ED of a "stable" patient who is sent home without follow-up arranged — the highest-frequency malpractice scenario.
— Failure to administer anti-D immunoglobulin to Rh-negative patients.
— Failure to ensure outpatient β-hCG follow-up after MTX — schedule it before discharge; do not rely on the patient to call.
— Drug interactions (NSAIDs, sulfa, PPIs) that compromise MTX efficacy.
Board pearl: Document, document, document: medical indication, alternatives discussed, shared decision-making, and follow-up plan — protects the patient and the clinician.
Step 3 management: Before discharge, confirm the patient understands warning signs in her own words (teach-back method) and has a confirmed appointment within 1 week.
— Stable hemodynamics
— Adnexal mass <3.5–4 cm
— Fetal cardiac activity absent
— End-organ function (renal, hepatic, marrow) normal
— β-hCG <5,000 mIU/mL (best success)
Board pearl: If the stem says "positive pregnancy test, no IUP on US, β-hCG 4,500" — the answer is ectopic, not "too early to see."
Step 3 management: Pattern-recognition cluster: positive β-hCG + lateralized pain + adnexal mass + free fluid → don't second-guess, treat as ectopic.
— "25-year-old G2P1 with 7 weeks amenorrhea, light vaginal bleeding, left lower quadrant pain. BP 118/72, HR 92. β-hCG 4,200, no IUP on TVUS, 2.5-cm left adnexal mass, no fetal cardiac activity, small cul-de-sac fluid. Hgb 12.4. Cr 0.8, AST/ALT normal."
— Answer: Methotrexate (meets all SAFE criteria).
— "28-year-old, syncope at home, BP 82/50, HR 130, peritoneal abdomen, positive β-hCG, free fluid throughout abdomen."
— Answer: Emergent laparoscopy/laparotomy; resuscitate concurrently. Do not select TVUS first or MTX.
— "Day 35 after IVF transfer, pelvic pain, β-hCG 12,000, US shows IUP with cardiac activity AND right adnexal mass with ring of fire."
— Answer: Laparoscopic salpingectomy (preserves IUP, avoids teratogenic MTX).
— Stable patient but β-hCG 12,000 with fetal cardiac activity in tube.
— Answer: Surgery — MTX likely to fail with cardiac activity.
— Patient on chronic TMP-SMX for HIV prophylaxis, otherwise meets MTX criteria.
— Answer: Surgery, not MTX (additive antifolate toxicity).
— Day 7: β-hCG fell only 8% from day 4.
— Answer: Second MTX dose (or surgery if rising or symptomatic).
— β-hCG 1,200, no IUP, no ectopic findings, asymptomatic.
— Answer: Repeat β-hCG in 48 hours and TVUS — do not give MTX yet.
— Rh-negative patient with ectopic.
— Answer: Anti-D immunoglobulin in addition to definitive treatment.
— Pregnant after BTL → ectopic until proven otherwise.
Board pearl: When a stem describes fetal cardiac activity in an adnexal mass, methotrexate is wrong — pick surgery.
Step 3 management: Recognize the "trap distractors": NSAIDs in med list, breastfeeding, mild renal insufficiency — each disqualifies MTX.
Ectopic pregnancy is implantation outside the uterine cavity that must be presumed in any reproductive-age patient with a positive β-hCG and pain, bleeding, or hemodynamic instability — diagnosed with quantitative β-hCG plus transvaginal ultrasound, treated with emergent surgery if unstable, methotrexate if SAFE-criteria-eligible, or laparoscopic salpingectomy/salpingostomy otherwise, with mandatory anti-D in Rh-negative patients, structured β-hCG follow-up until undetectable, and counseling on contraception, STI prevention, and future pregnancy planning.
Board pearl: Tachycardia in a pregnant patient is hemorrhage until proven otherwise; shoulder-tip pain or syncope in early pregnancy is a ruptured ectopic until imaging or laparoscopy says otherwise.
Step 3 management: The exam rewards systematic clusters — β-hCG + TVUS + type/Rh + CBC + OB consult — and clean discharge planning more than heroic management; close every loop before ending the encounter.